Biotechnology holds immense promise, yet its full potential remains untapped. To bridge this gap, the industry must embrace strategic shifts that streamline processes and enhance scalability. Central to this transformation are three pivotal strategies.

Arsenale is building a neo-industrial biomanufacturing company – one that integrates modular infrastructure, advanced sensing, and AI-enabled design to radically transform how biology is deployed at scale. As Chief Operating Officer, Arnaud Legris is connecting the dots across a complex system, with an evolving role as the company grows.

Precision fermentation represents a frontier in biotechnology, offering a sustainable method for producing high-value compounds. However, its widespread adoption beyond high-value compounds hinges on achieving cost parity with traditional production methods (and/or better performance).

After years of promises, industrial biotechnology stands at a pivotal juncture, where its potential can only be realized through deliberate and strategic actions.

The Bioyard is our platform for industrial-scale precision fermentation. Traditional biomanufacturing sites are often built around bio-pharma and around legacy infrastructure, which can be rigid, costly, and difficult to optimize. At Arsenale, we wanted to take a different approach.

Based in Pordenone, Arsenale Bioyards, a startup that wants to reduce the costs of a process to obtain organic alternatives to petrochemicals from yeasts and funghi.

This conversation is a masterclass in turning big vision into executable industrial strategy, and a rare peek into how deeptech founders can blend science, storytelling, and stoic leadership to win over top-tier VCs.

Scaling precision fermentation isn’t just about engineering microbes—it’s about building a biomanufacturing ecosystem that works at scale.

For the very first time, industry leaders and biotech startups have come together to form the AB4S Advanced Biotech for Sustainability Coalition.

For decades, industrial biotech has borrowed its manufacturing playbook from biopharma—and it’s been a costly mistake.

A Bessemer Moment for Biomanufacturing?
Explore how Arsenale Bioyards are shattering cost barriers in precision fermentation—driving a paradigm shift in industrial biotech.

L’azienda di Pordenone ha appena concluso un aumento di capitale per 10 milioni di euro, guidato da Cdp. Con la sua piattaforma end to end riprogramma geneticamente batteri e lieviti per trasformarli in strumenti di produzione di insulina, lattoferrina, collegene.

Arsenale Bioyards, azienda che vuole trasformare il mercate del bio-manufacturing, ha annunciato la chiusura del suo primo round di investimento seed da 10 milioni di euro

A proprietary, AI-driven end-to-end platform making biomanufacturing at scale economically viable – for the very first time

Massimo Portincaso: Pioneering Bio Manufacturing (Star Trek is Here?)

We caught up with Massimo Portincaso, the entrepreneur behind fledgling bio-manufacturing startup Arsenale.

On August 9th, 2023, the synthetic biology pioneer Amyris announced its voluntary filing for Chapter 11/Bankruptcy. I think this is a very important moment for the industry as it officially sanctions the end of an era, and (I hope) the beginning of a new one for the industry, and more in general for the transition of our industrial backbone from an exploitative to generative paradigm.

Not so long ago, the technology startup landscape in Europe was sparsely populated, especially when compared with other tech-rich regions of the world.

Corporates are sitting on a wealth of resources (not only financial) that could help European deeptech companies scale

Despite investment growing to more than $60 billion in 2020 and its massive disruption potential as the Fourth Wave of Innovation, deep tech is hindered by the current investment model.